Table 2.

Parameter estimates and bootstrap results from the final model^a

Parameter	θ estimate	Bootstrap
		Mean	% RSE	95% CI
Structural model parameters
CLirinotecan (L/hr)	43.8	43.8	5.19	(39.4, 48.5)
irinotecan VC (L)	153	152	6.49	(132, 172)
Qirinotecan (L/hr)	27.6	27.6	10.1	(22.3, 33.1)
irinotecan VP (L)	147	146	5.62	(132, 163)
CLAPC / FAPC (L/hr)	137	137	8.59	(116, 163)
APC VC / FAPC (L)	232	235	10.2	(190, 285)
QAPC / FAPC (L/hr)	125	127	18.8	(90.1, 183)
APC VP / FAPC (L)	234	234	9.84	(192, 282)
CLSN-38 / FSN-38 (L/hr)	1,760	1,749	8.95	(1,454, 2,050)
SN-38 VC / FSN-38 (L)	270	311	51.8	(34.7, 666)
QSN38 / FSN-38 (L/hr)	2,650	2,670	7.64	(2,276, 3,085)
SN-38 VP / FSN-38 (L)	26,300	26,700	13.6	(20,500, 34,900)
CLSN38G / FSN-38G (L/hr)	535	534	12.54	(406, 670)
SN-38G VC / FSN-38G (L)	82.6	80.0	16.88	(53.9, 106)
Between subject variability (as % CV)
CLirinotecan	32.1	32.2	13.5	(27.8, 36.3)
Irinotecan VC	43.7	44.4	31	(31.6, 58.2)
Qirinotecan	67.2	65.4	25	(45.4, 79.3)
Irinotecan VP	39.4	39.1	20.1	(31.0, 46.4)
CLAPC / FAPC	53.1	56.2	15.8	(45.7, 60.4)
APC VC / FAPC	72.7	73.4	21.6	(56.8, 87.7)
APC VP / FAPC	47.1	48.7	40.7	(28.2, 68.3)
CLSN-38 / FSN-38	46.6	45.7	20.6	(35.9, 54.6)
QSN-38 / FSN-38	67.5	66.5	19.6	(52.9, 78.7)
SN-38 VP / FSN-38	79.2	79.7	20.4	(63.7, 95.9)
CLSN-38G / FSN-38G	46.7	45.7	19.2	(36.8, 53.9)
Residual unexplained variability
N997D Additive (ng/mL)	0.26	0.27	23.9	(0.15, 0.40)
N997D Proportional (% CV)	10.5	10.5	18.6	(8.50, 12.4)
96-72-51 Additive (ng/mL)	0.013	0.018	164	(0.001, 0.048)
96-72-51 Proportional (% CV)	14.3	14.7	15.8	(12.4, 16.9)

^a959 successful bootstrap replicates

CV = coefficient of variation